Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Mark A. Elliott; Christine Favre‐Guilmard; Sai Man Liu; Jacquie Maignel; Geoffrey Masuyer; Matthew Beard; Christopher D. Boone; Denis Carré; Mikhail Kalinichev; Stéphane Lezmi; Imran Mir; Camille Nicoleau; Shilpa Palan; Cindy Périer; Elsa Raban; Sicai Zhang; Min Dong; Pål Stenmark; Johannes Krupp

doi:10.1126/sciadv.aau7196

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

in complex with peptides of hSyt2 and its homolog hSyt1. We demonstrate that neuronal surface receptor binding limits the clinical efficacy of unmodified BoNT/B and that modified BoNT/B proteins have promising clinical potential.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Elliott et al. (2019) studied this question.

synapsesocial.com/papers/6ab5e90e499a6d761e24a849 https://doi.org/10.1126/sciadv.aau7196

View Full Paper

Ask AI

Bookmark

Share

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Ask about this paper

Abstract

Discussion

Cite This Study

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading